---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-031624"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:52:32.795820+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences reports 2024 net revenue down 44% to $16.7M; net loss widens to $0.10/share

## Summary
- Net revenue $16.7M in 2024, down 44% from $29.6M in 2023 due to inventory shortage.
- Loss from operations of $1.9M vs income of $3.5M in 2023.
- Net loss $6.5M ($0.10 per share) vs net loss $3.7M ($0.07) in 2023.
- Cash at Dec. 31, 2024: $1.4M, down from $2.5M a year earlier.
- Management expects 2025 net revenues to reach or exceed 2024 levels.

## SEC filing metadata
- accession: 0001213900-25-031624
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390025031624/0001213900-25-031624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390025031624/ea0237926-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-031624
- JSON: https://secwatch.observer/filing/0001213900-25-031624.json
- Plain text: https://secwatch.observer/filing/0001213900-25-031624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.